Table 3.
Relevant researches of NCTD against invasion and metastasis for multiple cell lines in different cancer models
| Cancers | Cell lines | Basic mechanisms | Pathways | Accompanying roles | Experiment | References |
|---|---|---|---|---|---|---|
| Gallbladder cancer | GBC-SD | Upregulating TIMP-2 and MMP-2/TIMP-2 ratio, downregulating MMP-2 | In vitro | [142] | ||
| Colorectal cancer | CT26 | Downregulating MMP-9 and gelatinase; inhibiting the DNA-binding activity of Sp1 | Inhibiting Sp1 transcriptional activity | In vitro | [77] | |
|
HT-29 WiDr |
Downregulating αvβ6, MMP-3, MMP-9, N-cadherin, vimentin, p-ERK, p-Ets1; up-regulating E-cadherin | Inhibiting EMT by blocking αvβ6-ERK-Ets1 signaling pathway | [78] | |||
| CT26 | Down-expressing MMP-2, -9 and Desmoglein, N-cadherin, α- and β-catenin; reducing pulmonary metastasis. | Prolonging mice survival |
In vitro In vivo |
[74] | ||
| NSCLC |
A549 PC9 |
Inhibiting migration; enhancing the anticancer effects of gefitinib and cisplatin | Not altering p-EGFR | With gefitinib and cisplatin synergistic effect | In vitro | [54] |
|
A549 H1299 Calu6 |
Interfering the YAP-mediated cell progression and metastasis; inhibiting EMT, motile, invasion via enhancing E-cadherin and decreasing fibronectin/vimentin; repressing YAP and its downstream CYR61, CTGF | Repressing YAP signal pathway | [80] | |||
| A549 | Suppressing migration | Inhibiting p-Akt, NF-κB | With trichostatin A, celecoxib, lovastatin, synergistic effect |
In vitro Ex vivo |
[156] | |
| Breast cancer | MCF-7 | Inhibiting adhesion and migration, repressing cell adhesion to platelets via downregulating α2 integrin | Activating protein kinase C pathway via PP2A inhibition. via protein kinase C pathway-dependent, downregulation of α2 integrin | In vitro | [63] | |
| Hepatocellular cancer |
Huh7 SK-Hep1 |
Downregulating MMP-9, u-PA, p-ERK1/2, NF-kB, FAK; upregulating PAI-1 and TIMP-1 | Inhibiting the phosphorylation of ERK1/2 and NF-kB signaling pathway | In vitro | [170] | |
| SMMC-7721, MHCC-97H | Suppressing cell motility and invasiveness; up-regulating FAM46C; suppressing TGF-β/Smad signaling, EMT | Up-regulating FAM46C via brocking EMT process and TGF-β/Smad signaling | [9] | |||
|
HCCLM3 SMMC-7721 |
Inhibiting IL-6-induced EMT and cell invasiveness, and JAK/STAT3/TWIST signaling | Inhibiting IL-6-induced EMT via JAK2/STAT3/TWIST signaling | [81] | |||
| Osteosarcoma |
MG63 HOS |
Inhibiting the expression of MMP-2 and MMP-9 |
In vitro In vivo |
[22] | ||
| Giant cell tumor of bone (GCTB) | Inhibiting the EMT process | Modulating the miR-30a/MTDH/AKT cell signaling pathway | In vitro | [169] |